Denali Therapeutics Inc.
Price Action
Technical Summary
STAGE 2 UPTRENDDenali Therapeutics Inc. is in a confirmed Stage 2 uptrend, with price holding above all major moving averages and trend structure remaining intact. Relative strength is moderate (RS Rating: 55), indicating performance broadly in line with the market. Earnings contraction of 9% provides fundamental context to the price action. Investors should exercise caution due to high volatility (57% annualized), which requires wider risk management.
Trend Template (Minervini)
Price vs Moving Averages
| Period | Value | Spread | Signal |
|---|---|---|---|
| 20 SMA | $19.75 | +3.31% | ABOVE |
| 50 SMA | $20.12 | +1.40% | ABOVE |
| 100 SMA | $19.45 | +4.88% | ABOVE |
| 150 SMA | $18.58 | +9.77% | ABOVE |
| 200 SMA | $17.52 | +16.43% | ABOVE |
Price Performance
Technical Indicators
Risk Profile
Volume Analysis
Earnings Momentum
Growth Trends
Compounded Sales Growth
Compounded Profit Growth
Stock Price CAGR
Return on Equity
Key Metrics
Frequently Asked Questions
Is DNLI in an uptrend right now?
DNLI has a trend score of 4/4 based on Minervini's Stage Analysis. Yes, DNLI is in a Stage 2 uptrend with price above all major moving averages (50, 100, 150, 200 SMA) properly stacked.
Is DNLI overbought or oversold?
DNLI's RSI (14) is 45. The stock is in neutral territory, neither overbought nor oversold.
Is DNLI outperforming the market?
DNLI has a Relative Strength (RS) Rating of 55 out of 99. DNLI is performing about average compared to the market.
Where is DNLI in its 52-week range?
DNLI is trading at $20.40, which is 86% of its 52-week high ($23.77) and 70% above its 52-week low ($12.58).
How volatile is DNLI?
DNLI has a Beta of 1.82 and 52-week volatility of 57%. It's more volatile than the S&P 500 - expect bigger swings.